

1 **A review of *in vitro* and *in vivo* methods and their correlations to assess**
2 **mouthfeel of solid oral dosage forms.**

3 Abdullah Asiri^{1,2}, Justyna Hofmanová¹ and Hannah Batchelor³

- 4 1. School of Pharmacy, Institute of Clinical Sciences, College of Medical and Dental Sciences,
5 University of Birmingham, Birmingham, B15 2TT, UK
6 2. Faculty of Clinical Pharmacy, Albaha University, Alaqiq, 65779-77388, Saudi Arabia
7 3. Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161
8 Cathedral Street, Glasgow G4 0RE, United Kingdom

9
10 Corresponding author: Hannah Batchelor, (Hannah.batchelor@strath.ac.uk)

11 Telephone: +44 (0)141 548 2125

12
13 AA Orcid 0000-0001-5304-4398

14 JKH Orcid 0000-0003-4810-993X

15 HKB Orcid 0000-0002-8729-9951

16

17 Keywords: mouthfeel, texture, acceptability, palatability, dosage form

18

19

20 A teaser: This review analyses the relationship between instrumental and human data used to assess
21 the mouthfeel of solid oral dosage forms to provide recommendations on the most appropriate
22 methods to use in future studies.

23

24

25

26 **Word count: 5303**

27

28 **Abstract**

29 The oral sensory perception of medicines is an important quality attribute that can influence
30 adherence to medication. A systematic review identified studies reporting both *in vitro* and *in vivo*
31 data on the mouthfeel of solid oral dosage forms. Fifty-six studies were identified and included in
32 the analysis. Orodispersible tablets were the most commonly studied formulation (32/56 studies). *In*
33 *vivo* studies were typically conducted using untrained healthy adult volunteers where sample sizes
34 ranged from 3-75 participants. Only 8 studies reported a numeric correlation between the *in vitro*
35 and *in vivo* data presented. This review highlights opportunities for the development of a
36 standardised approach to assessment of mouthfeel to enable the development of optimised oral
37 pharmaceutical products.

38 Introduction

39 All sensory attributes (including mouthfeel, taste, smell and appearance) affect palatability and a
40 patient's willingness to take their medicine [1,2]. Palatability has been reported to affect the
41 acceptance of medicines where taste was reported to be the most significant attribute and has been
42 the subject of several reviews [3-9]. However, the mouthfeel, specifically texture of medicines has
43 previously been identified as a barrier in the oral acceptability of medicines yet there has been
44 limited work on this topic [10,11]. In sensory science, mouthfeel is defined as a physical sensation
45 which is created in the mouth by a product, as distinct from taste [12]. It encompasses sensations of
46 touch, pain and temperature (in comparison, texture is limited to the attributes of a product
47 perceptible by touch). As mouthfeel involves all aspects of oral interactions with a dosage form, the
48 overall perception is often complex and not limited to a single sensation. Assessment of the
49 acceptability of medicines is a relatively new regulatory concept, where regulatory guidance
50 introduced for paediatric medicines mandates acceptability testing for new products designed for
51 children [1]. Despite the surge of interest in acceptability/palatability assessment, there is limited
52 guidance on appropriate and reliable testing strategies.

53 Key mouthfeel attributes associated with the ingestion of medicine include lubrication; hardness;
54 adhesiveness; cohesiveness; grittiness and disintegration. Mouthfeel perception is affected by the
55 presence of saliva and intensity of mastication/chewing of the product which leads to disintegration
56 and dissolution of solid oral dosage forms and thus to changes in the sensory perception of the
57 product over time. Textural changes relate to the attrition of the dosage unit and the sensation of
58 particulate matter as well as release of viscous or adhesive materials from the formulation. These
59 multifactorial parameters make the development of *in vitro* and *in vivo* testing methods complex.

60 Mouthfeel attributes of oral medicines can be evaluated using sensory (*in vivo*) or instrumental (*in*
61 *vitro*) methods. It is recognised that human sensory analysis is the "gold-standard" to assess the
62 sensory perception of medicines, however, there is limited experience in the conduct of such studies
63 within pharmaceutical product development. Sensory studies are commonplace in food sciences
64 research, where a trained human panel evaluate sensory attributes of materials using reference
65 products as a control. Panellists are extensively trained in sensory assessment and use a clearly
66 defined lexicon of the terminology to assess each sensory attribute [13]. Sensory assessment differs
67 from consumer testing; consumer testing measures a hedonic response to a product thus a holistic
68 evaluation of the product rather than evaluation of specific defined attributes. For example, a
69 sensory panel will provide quantitative data on the sweetness of a product whereas a consumer
70 panel will report their degree of liking of the product under test. In the food sciences, consumer
71 responses can be correlated to sensory attributes via the sensory panel to inform product
72 development.

73 The assessment of sensory attributes of medicines largely differs compared to food, as medicines
74 are typically retained in the mouth for a much shorter time and the expectation from medicine is
75 very different to that experienced with food. A key factor in the design of a sensory study is the
76 definition of the attribute under evaluation and setting a specification target for this attribute (e.g.
77 hardness) [14], which is challenging for oral medicines due to the infancy of this field of research and
78 practice.

79 The only pharmacopoeial test that relates to a sensory attribute is the disintegration test that has
80 been adapted from the disintegration test for an immediate release conventional tablet to evaluate
81 orodispersible products where the conditions are far from those found in the oral cavity. The typical
82 volume in pharmacopoeial apparatus is > 800 mL compared to 0.7 mL of saliva in the oral cavity [15].

83 There is also an impact when using water compared to more biorelevant fluids (e.g. artificial saliva)
84 as this can affect the solubility and disintegration of materials [16]. This divergence in methodology
85 to assess oral disintegration is well recognised with a recent paper comparing several reported
86 methods to identify the one that gave the best correlation to *in vivo* data for a set of 6 tablets [17].

87 *In vivo* acceptance/palatability studies are associated with long timelines; high costs; the willingness
88 to navigate complex ethical processes; and high inter-subject variability, therefore there is a need to
89 better understand how *in vitro* methods can predict *in vivo* textural mouthfeel attributes of
90 medicines. It is recognised that *in vitro* methodologies possessing high prediction power for sensory
91 attributes would reduce the time and cost of drug development. Many *in vitro* methods to assess
92 mouthfeel have been reported in the literature, yet often the choice has stemmed from the
93 availability of apparatus and expertise within an organisation with no continuity in methodology or
94 agreement on a standardised technique. As sensory analysis is a relatively new aspect of
95 pharmaceutical product design and development, it is important to understand the relationship
96 between instrumental and human data, and then apply this knowledge to improve the development
97 of more acceptable/palatable medicines.

98 The aim of this review is to highlight the range of both *in vitro* and *in vivo* methodologies used to
99 assess mouthfeel attributes of solid oral dosage forms. A detailed analysis of methodologies used for
100 specific sensory attributes will guide the choice and development of suitable *in vitro* and *in vivo*
101 methods to ensure acceptable textural attributes of solid oral dosage forms under development.

102

103 **Identification of relevant literature**

104 **Search strategy**

105 A systematic and comprehensive literature search was conducted covering the time period from
106 January 1990 to April 2020. The following databases were searched: Web of Science, SCOPUS,
107 PROQUEST and EMBASE. The terms used to search the databases included: ('mouthfeel' OR 'texture'
108 OR 'acceptability' OR 'palatability' OR 'oral perception') AND ('medicine' OR 'drug' OR 'oral dosage
109 form' OR 'granule' OR 'tablet' OR 'odt' OR 'odf' OR 'orally disintegrating tablet' OR 'orally dispersible
110 tablet' OR 'orally dispersible film') AND ('rheology' OR 'tribology', 'texture analysis' OR 'disintegrate'
111 OR 'mechanical property') AND ('oral' OR 'mouth' OR 'buccal' OR 'tongue') as well as the derivatives
112 of these terms.

113 **Inclusion and exclusion criteria**

114 Only journal articles including *in vitro* and *in vivo* results on textural properties of solid oral dosage
115 forms were eligible for inclusion in the review. Papers that studied only taste or used animal models
116 (for *in vivo* aspects) in their experiments were excluded from the review. Only papers that included
117 original research where *in vivo* data was part of the study were included in the subsequent analysis.

118 The searches were performed by JH and AA and the decision on inclusion was made by all three
119 authors.

120 **Data Extraction**

121 The study characteristics, population demographics and outcomes of interest were manually
122 extracted from each study by a single reviewer, a subset was checked by HKB to ensure data capture
123 was accurate. Where possible statistical analysis was undertaken on the resulting data yet there was

124 a great deal of variability in the reporting thus qualitative descriptions of outcomes of interest are
125 also presented within the results.

126 **Analysis of literature identified**

127 In total 56 studies were identified where instrumental and human sensory data of mouthfeel were
128 available on solid oral medicines. Figure 1 shows the flow of our search and the results before and
129 after applying the inclusion-exclusion criteria.

130

131

132 **Formulations investigated**

133 Table 1 lists the mouthfeel attributes according to the formulations used as test samples within the
134 studies identified from the literature search. Formulations most often reported were those with
135 prolonged residence in the mouth, as compared with conventional tablets. Longer residence in the
136 mouth, inevitably, results in more pronounced sensory perception, hence the increased research
137 interest where disintegration time was the most reported attribute. The nomenclature in the
138 literature is not unified for orodispersible, orally disintegrating or orally dispersible tablets with
139 these terms being used interchangeably, all are also abbreviated to ODT. Following European
140 Pharmacopeia 10.0 they will be referred to as orodispersible (ODT) hereafter [18]. ODTs were the
141 most commonly studied formulation investigated in more than half (32/56, 57.1%) of the studies.

142

143 ***In vivo* methodologies reported**

144 *In vivo* cohort demographics

145 The demographics of the human participants involved in the *in vivo* assessments of mouthfeel are
146 provided in **Error! Reference source not found.** The majority of studies were conducted in healthy
147 volunteers, only one study involved volunteers with a history of swallowing difficulties, and 9/56
148 studies did not report the status of the participants' health. The age of participants was reported in
149 24/56 studies where the ages ranged from 18 to 80 years; 9 papers only reported the average age
150 and 22 papers did not state the age of the participants. The gender of the participants was reported
151 in 35/56 studies. There were 11 studies using a single gender (7 male only and 4 female only); in 16
152 studies there were more female participants compared to male; 4 studies with more male
153 participants and 4 studies that were balanced. The sample size used for the studies ranged from 3-75
154 participants with a mean value of 16.5 and a median of 12.

155 *In vivo* tools used

156 A variety of tools were provided for participants to assess their sensory perception of palatability
157 and mouthfeel of tested samples. A brief overview of the tools used is provided in Supplementary
158 **Error! Reference source not found.** By far, the most commonly reported tool was a scale where
159 participants rated given mouthfeel attributes. In most studies, sensory attributes were rated by
160 participants on structured multiple-point scales (e.g. 5-point scale). The scales which were marked
161 with hedonic terms (e.g. *very bad – very good*, *disliked – liked*) allowed participants to express their
162 hedonic subjective opinion. While on the scales marked with intensity modifiers (e.g. *low – high*,
163 *none – strong [roughness]*) or antonyms (e.g. *smooth – gritty*) participants could provide an objective
164 description of the sample. Several papers created bespoke scales; where mixed attributes were used

165 on a single scale, in these cases interpretation can be complex, e.g. 4-point scale with scores: gritty,
166 acceptable, good, excellent [19]. The second most reported type of scale was continuous scale, for
167 example, a visual analogue scale (VAS). Free text description was reported only as a supplementary
168 method of data collection.

169

170 ***In vitro* methodologies reported**

171 There are no standardised instrumental techniques that allow objective measurement of
172 texture/mouthfeel of solid oral dosage forms; therefore, multiple varying approaches have been
173 reported. Only 8 papers reported a numeric correlation between *in vitro* and *in vivo* data, yet data
174 was available to provide a numeric correlation (R^2 calculated as a linear correlation between the *in*
175 *vitro* and *in vivo* data) in an additional 15 papers. No non-linear relationships were reported to
176 correlate *in vitro* and *in vivo* data. In 37 papers evaluation of *in vitro* and *in vivo* disintegration time
177 and their correlation (non-numerical) was reported. Seventeen papers clearly stated relationships
178 between *in vitro* measurements and *in vivo* attributes, other than disintegration. Twenty-seven
179 papers reported using *in vitro* techniques with a potential to correlate with sensory perception but
180 did not further examine the correlation to the *in vivo* data. This section reviews the *in vitro* tools
181 reported in the literature. The details of methodologies used are grouped thematically based on the
182 sensory parameter under test and are presented in the tables below.

183

184 Disintegration

185 Although disintegration time is not a textural parameter in itself it can influence the perception of
186 mouthfeel for orodispersible products. Disintegration time was the most commonly reported
187 endpoint to compare *in vitro* and *in vivo* methods. This is likely to be a result of existing
188 requirements to measure the disintegration time of orodispersible formulations that prompts
189 research in this area (disintegration within < 3 min – [18] Eur. Pharm.10.0., or ; < 30 seconds – FDA
190 [20]). As compendial disintegration methods do not reflect the anatomy and physiology of oral
191 cavity, multiple more biorelevant methodologies have emerged to provide better correlation with *in*
192 *vivo* data. This divergence in methodology has previously been reviewed [17], [21].

193 The *in vitro* methodologies found in this literature search that include a correlation of disintegration
194 time with human data are presented in Supplementary Table 3. All formulations assessed were
195 either orodispersible tablets or films. The volume, media and temperature used in *in vitro* methods
196 were not consistent between papers: the volume ranged from ~30 μ L to 1000 mL; media used
197 included water, artificial saliva, ethanol:water or phosphate buffer; the most commonly reported
198 temperature was 37°C, but 25°C or room temperature was also reported. Only 8 of the 56 papers
199 reported a correlation coefficient value. Where correlation values were not provided, these have
200 been calculated for this manuscript assuming a linear relationship between variables.

201 Despite the variability in the methodology used, good correlations were shown in several studies
202 where the apparatus varied (R^2 values close to 1). It is complicated to identify the most promising
203 method from this data as the range of formulations evaluated and test conditions will determine the
204 output. There is also a potential for bias in the design and conduct of studies as only 3 were double-
205 blind studies. A previous review suggested that a biorelevant method designed by Narazaki et al
206 [22] gave the best correlation to human data, and in general biorelevant systems were better than
207 pharmacopoeial methods [17].

208 There is scope to correlate a range of *in vitro* data including wetting time; water absorption ratio;
209 contact angle and porosity (properties that determine how the formulation interacts with moisture);
210 to the dynamics of dosage form disintegration in the mouth; yet few studies explored the
211 relationships between these parameters.

212 Grittiness/roughness

213 In the sensory assessment of oral pharmaceuticals, the terms grittiness and roughness are often used
214 interchangeably. The interchangeable use is incorrect as, by definition, roughness relates to a degree
215 of irregularity/unevenness of the product's surface [23], while grittiness refers to the perception of
216 particles/granules and is usually a bulk characteristic [24]. A sensation of both roughness and
217 grittiness can occur when a product is administered as a powder/multiparticulate formulation;
218 disintegrates in the mouth or is chewed; hence, these formulations can be discussed together. Both,
219 disintegration and chewing result in a breakdown of the structure to smaller particles that can then
220 be swallowed either in this state or in a cohered state when mixed with saliva. The rate and resulting
221 size of disintegrated fragments are likely to affect the sensation of grittiness and roughness upon
222 ingestion of this type of dosage form. Indeed, the size of particles/granules was reported to relate to
223 the perceived grittiness and roughness of ODTs [25], multiparticulate formulations [25-27] and
224 chewable tablets [28] (Table 2). As excipients constitute a major fraction of the solid oral dosage
225 form mass, it is obvious that excipient type and ratio affects grittiness/roughness, as reported in
226 several studies [29] [30] [31] [32] [33] [34]. Consequently, the physical characterisation of API,
227 excipients as well as intermediate products (e.g. granules/pellets for tableting), is a method of
228 choice for prediction of grittiness and/or roughness of the final products. Apart from particle size
229 distribution, several methods, like particle hardness, sphericity and morphology (with optical or
230 scanning electron microscope, SEM), have been reported, although these factors have not been
231 directly linked to these mouthfeel attributes.

232 Unpleasant grittiness of an solid oral dosage form can be mitigated by co-administration with a
233 liquid/semiliquid vehicle (e.g. [35] and [26]). While thickened fluids were found to minimise the
234 sensation of grittiness of multiparticulate formulations of different sizes, water as a vehicle was not
235 sufficient [26]. No studies on vehicles for co-administration with ODT were found.

236 Most hard foods are chewed until the particles remaining are less than 2 mm prior to swallowing
237 [55]. A smooth preparation of a tablet dispersed in water prior to administration is the one where
238 the particles pass through a sieve screen with a nominal mesh aperture of 710 μm [56]. While for
239 ODT the size of core granules above 264 μm was reported to result in a rough mouthfeel [25]. This
240 size, however, is far above the sensitivity of the tongue; with particles as small 6-10 μm being
241 perceived [57].

242 *In vitro* methods that analyse the shape and sphericity of granules, or surface morphology of the
243 final dosage form can reveal information about roughness and grittiness yet there was little effort to
244 correlate these measures to *in vivo* data.

245 Adhesiveness/Cohesiveness

246 Adhesiveness (synonymously termed stickiness) reflects the extent to which a material adheres to
247 the tongue, teeth or palate. It can oppose lubrication as well as impede clearance from the oral
248 cavity. To measure adhesiveness there is a need to manipulate the product to replicate chewing and
249 mixing with saliva; this manipulation can change the properties of the material under test.

250 Adhesiveness is typically measured as the force required to separate the material under test from a

251 representative oral component (teeth, tongue or palate). Adhesiveness can be both a positive and
252 negative quality, depending on the type of product (e.g. mucoadhesive tablet vs. ODT).

253 Cohesiveness refers to the adhesion of the material under test to itself; often during the ingestion of
254 food it is chewed and mixed with saliva to form a cohesive bolus that is easier to swallow compared
255 to several smaller items. This can be complex to measure and often the material is measured at
256 several stages to replicate chewing and mixing with saliva using rheology or texture analysis.

257 In food sciences, adhesiveness and cohesiveness are measured by tensile testing apparatus or
258 texture analysers; similar equipment has been adapted for various solid oral dosage form testing
259 (Table 3). Only one paper reported a significant correlation between *in vitro* and *in vivo* stickiness,
260 which was for an ODF [58].

261 Hardness/softness

262 The force required to bite or chew food is of importance for those materials designed to be chewed
263 prior to swallowing. Most solid oral dosage forms are designed to be swallowed without chewing
264 however chewable tablets and chewing gums are obvious exceptions. Hardness/softness of these
265 formulations was related to the composition of the dosage form (**Error! Reference source not
266 found.**) [28,53] . Instrumentally, hardness/softness was measured using compression cycles which
267 imitate a bite (e.g. force required for deformation of a sample) [53].

268 The sensory attribute of hardness/softness can be linked to other textural properties, in one *in vivo*
269 study participants were asked to rate the consistency and chewability of the gum which is related to
270 the hardness but not a direct measure of this property [53].

271

272

273 Oiliness

274 Perception of oiliness was mentioned only in one study. It was specific to an emulsion-based
275 formulation, where low stability of the emulsion under mastication resulted in an oily mouthfeel
276 [28]. The oiliness of the soft chewable tablet was related to the type and ratio of the emulsifier used
277 in the formulation [28]; this study is a good example of case-specific optimisation of product
278 mouthfeel.

279

280 “Consumer insights” into the palatability/mouthfeel of formulations

281 As stated in the introduction, sensory analysis provides a quantitative measure of an individual
282 attribute, however, consumer feedback is related to a hedonic experience of the whole product. In
283 the reviewed literature the terms palatability, mouthfeel and acceptance were used
284 interchangeably, as a measure of participants’ subjective hedonic and holistic opinion of the
285 formulation under test. The majority of papers failed to include a definition of palatability,
286 mouthfeel or acceptance. In general, these terms were used appropriately, yet there were some
287 examples of incorrect use, e.g. palatability reported as a measure of ease of taking the formulation
288 [42].

289 Palatability is one of the key acceptability attributes of oral medicine. It is defined as “the overall
290 appreciation of an (often oral) medicinal product in relation to its smell, taste, aftertaste and texture
291 (i.e. feeling in the mouth)” [1]. Hence, palatability is a hedonic evaluation that is subjective in nature.

292 Several studies attempted to relate palatability/mouthfeel/acceptance to a specific *in vitro*
293 parameter, like granule/particle size [61] [25], coating thickness [62], or proportion of insoluble
294 materials [61] (Table). In these cases, the palatability/ mouthfeel/acceptance was assumed to be
295 driven by a dominant attribute like grittiness/roughness. However, it should be recognized, that for
296 the majority of formulations the palatability is a function of multiple sensory attributes rather than a
297 single factor. Thus, interpretation and correlations between *in vitro* and *in vivo* data are complex and
298 a single *in vitro* test to predict palatability is unlikely to exist.

299 An exemplary study that included multiple parameters was reported by Casian et al. [36]. In this
300 study, the authors predicted the palatability of ODTs using partial least squares (PLS) modelling,
301 which is a high-throughput predictive statistical method. The model was built using a set of ODTs
302 selected by a design of experiments (DoE) approach. The data input used to train the model was
303 based on formulation characteristics (including filler ratio or granule size), multiple parameters
304 obtained via texture analysis testing, and *in vivo* sensory data. This approach demonstrated a
305 reliable prediction of the holistic palatability of ODTs.

306 Ease of administration/swallowing

307 For conventional tablets (which are swallowed whole) the ease of administration is understood as
308 the ability of the patient to swallow the formulation, and it is mainly attributed to the size of the
309 formulation [27]and [1,2]. The regulatory definition of acceptability has been reported as “an overall
310 ability of the patient and caregiver (defined as ‘user’) to use a medicinal product as intended (or
311 authorised)” [68] and “the ability and willingness of a patient to self-administer, and also of any of
312 their lay or professional caregivers, to administer a medicinal product as intended” [2]. Thus, the
313 ability to administer and swallow a solid oral dosage form is fundamental for its acceptance.

314 A range of factors come into play for a formulation which disintegrates/dissolves/is chewed in the
315 mouth and then swallowed gradually. In such cases, a barrier to administration may arise from the
316 need to use water (with an ODT) or the fragility of the formulation (of an ODF) (Table 5). While ease
317 of administration is relatively easy to evaluate using a human panel, it is difficult to replicate these
318 processes *in vitro*. To date, only two papers reported a relationship between *in vivo* and *in vitro* data
319 for the ease of administration/swallowing [27] [69] (Table 5). A notable example is the throat model
320 which mimics the process of swallowing [69]; the authors reported a relationship between speed of
321 bolus ejection in the model and perception of ease of swallowing of multiparticulate formulation in a
322 viscous vehicle. Although the relationship was not linear, the model correlated to sensory studies
323 and enabled an understanding of the mechanisms involved in swallowing oral medicines.

324

325 Time-dependent sensory assessment

326 The sensory perception of oral medicine can extend beyond administration, the sensation in the
327 mouth can linger and be unpleasant for the patient. Multiple examples of sensations following
328 administration were reported (Table 6), where the most common were residue in the mouth and
329 need to drink water. Both related to characteristics of the formulation, which may be difficult to
330 clear from the oral cavity. Some papers reported that these two sensations related to a specific *in*
331 *vitro* parameter, i.e. granule size [25], particle size [27], [69], or type of co-administration vehicle
332 [27] [69]. The amount of residue in the mouth was also predicted by PLS modelling based on
333 formulation characteristics and disintegration behaviour [36].

334 In addition, sensations like numbness or astringency [62] [43] [46] [38] [41] [45] following
335 administration, are more likely to be specific to the API rather than formulation attributes. For

336 example, greater coating thickness of API containing granules was related to reduced numbness
337 [62].

338 ***In vivo-in vitro* correlations reported**

339 There are four major incentives to seek correlations between an *in vitro* method and sensory data
340 for oral medicines: (i) to provide a tool for quality control; (ii) predict consumer preference (iii)
341 understand processes underlying mouthfeel perception, as well as (iv) replace human panels for
342 sensory evaluation and consequently reduce the costs of evaluation [70].

343 From a statistical point of view, establishing a meaningful relationship between *in vitro* and *in vivo*
344 data can be done at several levels. First, by searching for simpler links, like agreement in the rank
345 order of sensory assessment and instrumentally obtained values; such correlations can inform and
346 direct further research. Establishing correlations between instrumental data and mouthfeel
347 perception is challenging. While for the taste of solid oral dosage forms (beyond the scope of this
348 review) correlations with *in vitro* data have already been established using several methods (e.g. e-
349 Tongue [71,72] or BATA rat studies [73]), research on mouthfeel is limited. The most common
350 correlations within sensory science that correlate food texture to instrumental methods are partial
351 least squares regression which highlights linear relationships [74]. In this work linear relationships
352 were evaluated to determine any likely correlations. However, there is scope to explore non-linear
353 relationships and to develop principal component analysis maps of textures of oral medicines to
354 better understand the correlation between *in vitro* and *in vivo* data [75].

355 In this literature review the majority of studies reported *in vitro in vivo* relationships using simple
356 comparative methods. Additionally, some studies established whether the samples were statistically
357 different (e.g. via t-test or Wilcoxon signed rank test, Tables 4-9). The relationship between human
358 sensory perception was reported for two types of data: composition of the formulation (9 studies,
359 refs: [28] [29] [30] [31] [33] [34] [53] [58] [63]), and physical properties of the formulation (10
360 studies, ref: [25] [26] [27] [36] [39] [53] [58] [61] [62] [69]).

361 Meaningful *in vitro in vivo* correlations were reported only for disintegration time (linear correlation
362 coefficient), whereas no paper stated a numerical value of the correlation for other mouthfeel
363 parameters. Two papers did apply advanced statistical tools to predict mouthfeel or palatability.
364 Specifically, Casian et al [36] used PLS modelling to predict ODTs palatability based on (i) bespoke
365 instrumental measure of disintegration profile and (ii) multiple formulation characteristics. While
366 Lopez et al. [26] modelled perception of multiparticulate formulation grittiness using multiple linear
367 regression. The prediction was based on multiparticulate formulation size, amount and viscosity of
368 administration vehicle. The value of these approaches lies in the recognition of the complexity and
369 multitude of factors that affect sensory perception.

370 The choice of excipient, like disintegrant/filler/softener/emulsifier, was found to affect the
371 mouthfeel. Such information benefits the design of more palatable products, as it enables selection
372 of appropriate excipients, for example, a disintegrant that provides the least rough ODT (e.g. use of
373 croscarmellose sodium results in rougher ODT than one with crospovidone [31]).

374 Once the main formulation-based determinants of sensory perception are known, more complex
375 testing and analytical methods can be performed to obtain meaningful correlations with *in vivo* data
376 [70]. Robust correlations can increase understanding of the processes underlying sensory attributes
377 that inform mouthfeel perception relating to oral pharmaceutical products. Finally, this knowledge
378 can be leveraged to build a multifactorial model of sensory perception which can predict *in vivo* data
379 based on *in vitro* input. The gaps in knowledge on key mouthfeel characteristics of formulations

380 coupled with the lack of application of advanced statistical correlations have limited the progression
381 of *in vitro* methods to measure sensory properties of solid oral dosage forms.

382 There have been developments in *in vitro* methods to better replicate aspects of the anatomy and
383 physiology of the mouth and thus provide better correlations to sensory data. For example, simpler
384 adaptations to the texture analyser to measure force response to assess specific properties of
385 medicines including adhesiveness of ODF [58]; hardness, elasticity, gumminess, adhesiveness of
386 pastille [67]; elasticity of chewing gum [59]. More complex modifications of texture analyser were
387 designed to measure disintegration profile of ODT, which controlled not only force response but also
388 mimicked the temperature, humidity and saliva flow of the oral cavity [16] [76]. A further
389 noteworthy example is a throat model that imitates the swallowing [69]. Such bespoke apparatuses
390 are of value as they allow to observe oral processing or swallowing of oral dosage forms in mouth
391 like conditions and understand processes underlying mouthfeel perception.

392

393 **Standardisation of sensory analysis for pharmaceutical products**

394 Achieving robust and applicable correlations between instrumental and human data is not possible
395 without standardisation of methodology. Sensory analysis provides a more accurate measure of
396 human perception compared to *in vitro* methods [77]. Refinement, development and harmonization
397 of sensory methodologies within the pharmaceutical field have already been advocated [9].

398 The literature revealed that untrained (healthy) volunteers are typically used as study participants in
399 pharmaceutical sensory assessment. This poses a significant difference from food sensory sciences,
400 where trained panels are used to provide an objective description of sensory perception, while
401 untrained participants (e.g. patients, consumers) to give a subjective hedonic opinion of the product
402 [78]. Lack of training can result in subjective use of scales [79]. In the papers identified only one
403 paper specified training of the panellists [26]. In this study, the panellists were trained with
404 references for negative and positive controls to mark extreme ends of a grittiness scale for
405 evaluation of multiparticulate formulation [26]. Admittedly, obtaining reference samples relevant for
406 oral pharmaceutical products panel is a challenge. In pharmaceuticals, due to the infancy of the field,
407 untrained participants are performing both sensory and hedonic evaluations within the same test.

408 The definition of the attribute under evaluation is a key factor in robust study design. A further
409 difficulty in developing and standardizing sensory methodologies relates to the vast diversity of oral
410 pharmaceutical products. Depending on the formulation, the residence time in the mouth, level of
411 mastication and disintegration profile will differ. This poses a challenge to identify and select specific
412 test methods and attributes for appropriate characterisation.

413 Standardization of terminology would facilitate clear communication between human sensory panel
414 members, investigators and other scientists, and subsequently, increase the quality of
415 pharmaceutical sensory studies. In addition, standardised tools would enable comparison across
416 studies that would reduce the need for reference samples that are common in food science. In
417 general, the terminology used within studies was correct, although some papers did not include
418 definitions of measured attributes including the most basic terms including acceptability or
419 palatability. In rare examples, the tool used to collate information on the evaluated mouthfeel
420 attribute was confusing (e.g. *no gritty taste observed* [28] or scales that mixed sensory and hedonic
421 terms (e.g. *gritty, acceptable, good, excellent*) [38] [46].

422

423 **Conclusions**

424 There is extensive literature that reports on the *in vitro* assessment of sensory attributes of solid oral
425 medicines yet fewer that correlate *in vitro* to *in vivo* data.

426 Sensory attributes of oral formulations affect the acceptability of medicines and thus have an impact
427 on patient safety, therapeutic outcomes and adherence. However, distinct differences in the key
428 sensory attributes for a range of oral formulations means that separate considerations are required
429 in the design of both *in vitro* and *in vivo* tests to better understand how these attributes affect
430 patients overall hedonic response.

431 The value of instrumental measurements lies in their ability to generate high-throughput and
432 objective, repeatable data. It is important to understand the relationship between instrumental and
433 human data, and then apply this knowledge to speed up the development of more
434 acceptable/palatable medicines. As sensory assessment within pharmaceutical science is in its
435 infancy efforts should be focused on standardisation of testing strategies to maximise the translation
436 of *in vitro* methodology and *in vivo* data whilst minimising the burden to participants.

437

438

- 442 **1** EMA. (2013) Guideline on pharmaceutical development of medicines for paediatric use.
443 (Vol. 05.02.2020), European Medicines Agency
- 444 **2** EMA. (2017) Reflection paper on the pharmaceutical development of medicines for use in
445 the older population. (Vol. 25.02.2020), European Medicines Agency
- 446 **3** Davies, E.H. and Tuleu, C. (2008) Medicines for Children: A Matter of Taste. *Journal of*
447 *Pediatrics* 153 (5), 599-604
- 448 **4** Hanning, S.M. et al. (2016) Patient centric formulations for paediatrics and geriatrics:
449 Similarities and differences. *International Journal of Pharmaceutics* 512 (2), 355-359
- 450 **5** Liu, F. et al. (2014) Patient-Centred Pharmaceutical Design to Improve Acceptability of
451 Medicines: Similarities and Differences in Paediatric and Geriatric Populations. *Drugs* 74 (16),
452 1871-1889
- 453 **6** Mennella, J.A. et al. (2015) Children's perceptions about medicines: individual differences
454 and taste. *Bmc Pediatrics* 15
- 455 **7** Mohamed-Ahmed, A.H.A. et al. (2016) Non-human tools for the evaluation of bitter taste in
456 the design and development of medicines: a systematic review. *Drug Discovery Today* 21 (7),
457 1170-1180
- 458 **8** Walsh, J. et al. (2014) Playing hide and seek with poorly tasting paediatric medicines: Do not
459 forget the excipients. *Advanced Drug Delivery Reviews* 73, 14-33
- 460 **9** Ternik, R. et al. (2018) Assessment of swallowability and palatability of oral dosage forms in
461 children: Report from an M-CERSI pediatric formulation workshop. *International Journal of*
462 *Pharmaceutics* 536 (2), 570-581
- 463 **10** Planchette, C. et al. (2016) Printing medicines as orodispersible dosage forms: Effect of
464 substrate on the printed micro-structure. *International Journal of Pharmaceutics* 509 (1-2),
465 518-527
- 466 **11** Venables, R. et al. (2015) Problems with oral formulations prescribed to children: a focus
467 group study of healthcare professionals. *International Journal of Clinical Pharmacy* 37 (6),
468 1057-1067
- 469 **12** Mouritsen, O.G. et al. (2017) *Mouthfeel: How Texture Makes Taste*, Columbia University
470 Press
- 471 **13** Nishinari, K. and Fang, Y. (2018) Perception and measurement of food texture: Solid foods.
472 *Journal of Texture Studies* 49 (2), 160-201
- 473 **14** Beeren, C.J.M. (2010) 5 - Establishing product sensory specifications. In *Sensory Analysis for*
474 *Food and Beverage Quality Control* (Kilcast, D., ed.), pp. 75-96, Woodhead Publishing
- 475 **15** Müller, K. et al. (2010) Measurement of saliva volume in the mouth of members of a trained
476 sensory panel using a beetroot (*Beta vulgaris*) extract. *Food Quality and Preference* 21 (5),
477 569-574
- 478 **16** Abdelbary, G. et al. (2005) Determination of the in vitro disintegration profile of rapidly
479 disintegrating tablets and correlation with oral disintegration. *International Journal of*
480 *Pharmaceutics* 292 (1), 29-41
- 481 **17** Brniak, W. et al. (2015) The practical approach to the evaluation of methods used to
482 determine the disintegration time of orally disintegrating tablets (ODTs). *Saudi*
483 *Pharmaceutical Journal* 23 (4), 437-443
- 484 **18** Council of Europe. (2019) European Pharmacopoeia 10.0. Council of Europe
- 485 **19** Auda, S.H. et al. (2014) Design, formulation and characterization of fast dissolving films
486 containing dextromethorphan. *Digest Journal of Nanomaterials and Biostructures* 9 (1), 133-
487 141
- 488 **20** FDA. (2008) Guidance for Industry Orally Disintegrating Tablets. (Vol. 15.04.2020) ((CDER),
489 C.f.D.E.a.R., ed.), Food and Drug Administration

- 490 **21** Ali, S. and Kolter, K. (2014) A Recent Advancement in Orally Disintegrating Formulations.
 491 *American Pharmaceutical Review*:
 492 ([https://www.americanpharmaceuticalreview.com/Featured-Articles/163474-A-Recent-](https://www.americanpharmaceuticalreview.com/Featured-Articles/163474-A-Recent-Advancement-in-Orally-Disintegrating-Formulations/)
 493 [Advancement-in-Orally-Disintegrating-Formulations/](https://www.americanpharmaceuticalreview.com/Featured-Articles/163474-A-Recent-Advancement-in-Orally-Disintegrating-Formulations/))
- 494 **22** Narazaki, R. et al. (2004) A new method for disintegration studies of rapid disintegrating
 495 tablet. *Chemical & Pharmaceutical Bulletin* 52 (6), 704-707
- 496 **23** Civile, G.V. et al. (2010) Development of an almond lexicon to assess the sensory properties
 497 of almond varieties. *Journal of Sensory Studies* 25 (1), 146-162
- 498 **24** International Organization for Standardization. (2008) Sensory analysis — Vocabulary (ISO
 499 5492:2008(en)) International Organization for Standardization
- 500 **25** Kimura, S.I. et al. (2015) Effect of granule properties on rough mouth feel and palatability of
 501 orally disintegrating tablets. *International Journal of Pharmaceutics* 484 (1-2), 156-162
- 502 **26** Lopez, F.L. et al. (2016) Effect of formulation variables on oral grittiness and preferences of
 503 multiparticulate formulations in adult volunteers. *European Journal of Pharmaceutical*
 504 *Sciences* 92, 156-162
- 505 **27** Lopez, F.L. et al. (2018) The effect of administration media on palatability and ease of
 506 swallowing of multiparticulate formulations. *International Journal of Pharmaceutics* 551 (1-
 507 2), 67-75
- 508 **28** Mishra, B. et al. (2009) Investigation of organoleptic characteristics in the development of
 509 soft chews of calcium carbonate as mineral supplement. *Yakugaku Zasshi* 129 (12), 1537-
 510 1544
- 511 **29** Amelian, A. and Winnicka, K. (2012) Effect of the type of disintegrant on the characteristics
 512 of orally disintegrating tablets manufactured using new ready-to-use excipients (Ludiflash (R)
 513 or Parateck (R)) by direct compression method. *African Journal of Pharmacy and*
 514 *Pharmacology* 6 (31), 2359-2367
- 515 **30** Douroumis, D.D. et al. (2011) Development and evaluation of cetirizine HCl taste-masked
 516 oral disintegrating tablets. *AAPS PharmSciTech* 12 (1), 141-151
- 517 **31** Gryczke, A. et al. (2011) Development and evaluation of orally disintegrating tablets (ODTs)
 518 containing Ibuprofen granules prepared by hot melt extrusion. *Colloids and Surfaces B:*
 519 *Biointerfaces* 86 (2), 275-284
- 520 **32** Samprasit, W. et al. (2012) Preparation and evaluation of taste-masked dextromethorphan
 521 oral disintegrating tablet. *Pharmaceutical Development and Technology* 17 (3), 315-320
- 522 **33** Liu, Y. et al. (2018) A novel and discriminative method of in vitro disintegration time for
 523 preparation and optimization of taste-masked orally disintegrating tablets of carbinoxamine
 524 maleate. *Drug Development and Industrial Pharmacy* 44 (8), 1317-1327
- 525 **34** Han, X.Z., Shan: Chai, Zhuodong: Dong, Yangyun: He, Wei: Yin, Lifang: Yang, Lei: Qin, Chao.
 526 (2019) In vitro and in vivo evaluation of the taste-masking efficiency of Amberlite IRP88 as
 527 drug carries in chewable tablets. *Journal of Drug Delivery Science and Technology* 49, 547-
 528 555
- 529 **35** Kluk, A. and Sznitowska, M. (2014) Application properties of oral gels as media for
 530 administration of minitables and pellets to paediatric patients. *International Journal of*
 531 *Pharmaceutics* 460 (1-2), 228-233
- 532 **36** Casian, T. et al. (2018) Assessment of oral formulation-dependent characteristics of
 533 orodispersible tablets using texture profiles and multivariate data analysis. *Journal of*
 534 *Pharmaceutical and Biomedical Analysis* 152, 47-56
- 535 **37** Wang, C.G. et al. (2017) Expedited Development of Diphenhydramine Orally Disintegrating
 536 Tablet through Integrated Crystal and Particle Engineering. *Molecular Pharmaceutics* 14 (10),
 537 3399-3408
- 538 **38** Shazly, G.A. and Ibrahim, M.A. (2016) Losartan potassium taste-masked oral disintegrating
 539 tablets for hypertensive patients. *Latin American Journal of Pharmacy* 35 (1), 110-117

- 540 **39** Wagner-Hattler, L. et al. (2017) In vitro characterization and mouthfeel study of
541 functionalized calcium carbonate in orally disintegrating tablets. *International Journal of*
542 *Pharmaceutics* 534 (1-2), 50-59
- 543 **40** Bin Liew, K. et al. (2015) Taste-masked and affordable donepezil hydrochloride orally
544 disintegrating tablet as promising solution for non-compliance in Alzheimer's disease
545 patients. *Drug Development and Industrial Pharmacy* 41 (4), 583-593
- 546 **41** Uchida, T. et al. (2013) Evaluation of palatability of 10 commercial amlodipine orally
547 disintegrating tablets by gustatory sensation testing, OD-mate as a new disintegration
548 apparatus and the artificial taste sensor. *Journal of Pharmacy and Pharmacology* 65 (9),
549 1312-1320
- 550 **42** Chono, S. et al. (2017) Physicochemical qualities and ingestibility of high value-added
551 amlodipine besilate formulations. *Journal of Generic Medicines* 13 (1), 28-33
- 552 **43** Nakano, Y. et al. (2013) Preparation and evaluation of unpleasant taste-masked pioglitazone
553 orally disintegrating tablets. *International Journal of Pharmaceutics* 446 (1-2), 160-165
- 554 **44** Iqbal, H.N., Shazia: Ali, Huma: Bashir, Lubna: Zafar, Farya: Akram, Saadia: Yasmin, Riffat:
555 Ghayas, Sana: Israr, Fozia: Akifuddin,. (2020) Formulation development and optimization
556 studies of mouth dissolving tablets of tizanidine HCl. *Pakistan Journal of Pharmaceutical*
557 *Sciences* 33 (1(Supplementary)), 245-251
- 558 **45** Mahrous, G.M.I., Mohamed Abbas: Mostafa, Haitham Fady: Elzayat, Ehab Mostafa. (2019)
559 Application of a quality-by-design approach for utilizing sodium stearyl fumarate as a taste-
560 masking agent in dextromethorphan hydrobromide orally disintegrating tablets.
561 *Pharmaceutical Development and Technology* 24 (6), 711-719
- 562 **46** Mahrous, G.M. et al. (2016) Formulation and evaluation of orally disintegrating clopidogrel
563 tablets. *Brazilian Journal of Pharmaceutical Sciences* 52 (2), 309-317
- 564 **47** Han, X. et al. (2020) Development and evaluation of novel innovative multi-channel
565 aripiprazole orally disintegrating tablets. *Journal of Drug Delivery Science and Technology* 55,
566 101446
- 567 **48** Yu, J.S., X.: Chen, S.: Sun, X.: Song, P.: Zhao, R.: Hu, L. (2020) Preparation and evaluation of
568 novel multi-channel orally disintegrating tablets. *European Journal of Pharmaceutical*
569 *Sciences* 142 (no pagination)
- 570 **49** Auda, S.H.A.-O., Abdullah H.: Alanazi, Fars K.: Badran, Mohamed M.: Shakeel, Faiyaz. (2019)
571 Design, characterization and evaluation of oral fast dissolving polymeric films of isradipine
572 inclusion complex. *Polymer Bulletin* 76 (5), 2453-2469
- 573 **50** Samprasit, W. et al. (2018) Cyclodextrin-based oral dissolving films formulation of taste-
574 masked meloxicam. *Pharmaceutical Development and Technology* 23 (5), 530-539
- 575 **51** Auda, S.H. et al. (2014) Development, preparation and evaluation of oral dissolving films
576 containing metoclopramide. *Latin American Journal of Pharmacy* 33 (6), 1027-1033
- 577 **52** Bin Liew, K. et al. (2012) Characterization of Oral Disintegrating Film Containing Donepezil
578 for Alzheimer Disease. *AAPS PharmSciTech* 13 (1), 134-142
- 579 **53** Paradkar, M. et al. (2016) Formulation development and evaluation of medicated chewing
580 gum of anti-emetic drug. *Saudi Pharmaceutical Journal* 24 (2), 153-164
- 581 **54** Labib, G.S. (2015) Novel levocetirizine HCl tablets with enhanced palatability: Synergistic
582 effect of combining taste modifiers and effervescence technique. *Drug Design, Development*
583 *and Therapy* 9, 5135-5146
- 584 **55** Jalabert-Malbos, M.L. et al. (2007) Particle size distribution in the food bolus after
585 mastication of natural foods. *Food Quality and Preference* 18 (5), 803-812
- 586 **56** WHO. (2011) Revision of monograph on tablets. In *Document QAS/09.324/Final* (Vol.
587 21.07.2020) (Preparations, E.C.o.S.f.P., ed.), World Health Organization
- 588 **57** Imai, E. et al. (1995) Oral perception of grittiness: Effect of particle size and concentration of
589 the dispersed particles and the dispersion medium. *Journal of Texture Studies* 26 (5), 561-
590 576

591 **58** Scarpa, M. et al. (2018) Key acceptability attributes of orodispersible films. *European Journal*
592 *of Pharmaceutics and Biopharmaceutics* 125, 131-140

593 **59** Aslani, A. et al. (2016) Design, formulation, and evaluation of ginger medicated chewing
594 gum. *Advanced Biomedical Research* 5, 130-130

595 **60** Aslani, A. et al. (2014) Design, formulation and evaluation of green tea chewing gum.
596 *Advanced Biomedical Research* 3, 142-142

597 **61** Dziemidowicz, K. et al. (2018) Co-Processed Excipients for Dispersible Tablets—Part 2:
598 Patient Acceptability. *AAPS PharmSciTech* 19 (6), 2646-2657

599 **62** Matsui, R. et al. (2015) Combination effect of physical and gustatory taste masking for
600 propiverine hydrochloride orally disintegrating tablets on palatability. *Biological and*
601 *Pharmaceutical Bulletin* 38 (1), 17-22

602 **63** Takano, H.U., Shinya: Kashiwagura, Yasuharu: Tanaka, Shimako: Hakamata, Akio: Odagiri,
603 Keiichi: Inui, Naoki: Watanabe, Hiroshi: Namiki, Noriyuki. (2019) Preparation of Cocoa
604 Powder-Containing Orally Disintegrating Tablets of Rebamipide (Rebamipide Chocolet) and
605 Evaluation of Their Clinical Palatability. *Chemical & Pharmaceutical Bulletin* 67 (2), 112-119

606 **64** Grady, H. et al. (2018) Evaluation of Physical Characteristics of Dexamethasone Orally
607 Disintegrating Tablets. *Pharmaceutical Technology Europe* 30 (8), 18-23

608 **65** Elmeshad, A.N. and El Hagrasy, A.S. (2011) Characterization and optimization of
609 orodispersible mosapride film formulations. *AAPS PharmSciTech* 12 (4), 1384-1392

610 **66** Shamma, R. and Elkasabgy, N. (2016) Design of freeze-dried Soluplus/polyvinyl alcohol-based
611 film for the oral delivery of an insoluble drug for the pediatric use. *Drug Delivery* 23 (2), 489-
612 499

613 **67** Silva, F.C. et al. (2017) Nystatin and lidocaine pastilles for the local treatment of oral
614 mucositis. *Pharmaceutical Development and Technology* 22 (2), 266-274

615 **68** Kozarewicz, P. (2014) Regulatory perspectives on acceptability testing of dosage forms in
616 children. *International Journal of Pharmaceutics* 469 (2), 245-248

617 **69** Marconati, M. et al. (2019) In vitro and sensory tests to design easy-to-swallow multi-
618 particulate formulations. *European Journal of Pharmaceutical Sciences* 132, 157-162

619 **70** Szczesniak, A.S. (1987) Correlating sensory with instrumental texture measurements - an
620 overview of recent developments. *Journal of Texture Studies* 18 (1), 1-15

621 **71** Nakamura, H. et al. (2015) The prediction of the palatability of orally disintegrating tablets
622 by an electronic gustatory system. *International Journal of Pharmaceutics* 493 (1-2), 305-312

623 **72** Uchida, T. et al. (2003) Evaluation of the bitterness of antibiotics using a taste sensor.
624 *Journal of Pharmacy and Pharmacology* 55 (11), 1479-1485

625 **73** Soto, J. et al. (2018) Rats can predict aversiveness of Active Pharmaceutical Ingredients.
626 *European Journal of Pharmaceutics and Biopharmaceutics* 133, 77-84

627 **74** de Kermadec, F.H. et al. (1997) Comparison between linear and nonlinear PLS methods to
628 explain overall liking from sensory characteristics. *Food Quality and Preference* 8 (5), 395-
629 402

630 **75** Borgognone, M.a.G. et al. (2001) Principal component analysis in sensory analysis:
631 covariance or correlation matrix? *Food Quality and Preference* 12 (5), 323-326

632 **76** Koner, J.S. et al. (2019) Conceptualisation, Development, Fabrication and In Vivo Validation
633 of a Novel Disintegration Tester for Orally Disintegrating Tablets. *Scientific Reports* 9

634 **77** Ross, C.F. (2009) Sensory science at the human-machine interface. *Trends in Food Science &*
635 *Technology* 20 (2), 63-72

636 **78** Yang, J. and Lee, J. (2019) Application of Sensory Descriptive Analysis and Consumer Studies
637 to Investigate Traditional and Authentic Foods: A Review. *Foods* 8 (2)

638 **79** Lim, J.Y. (2011) Hedonic scaling: A review of methods and theory. *Food Quality and*
639 *Preference* 22 (8), 733-747

- 640 **80** Basalious, E.B. et al. (2014) Utility of Mannitol and Citric Acid for Enhancing the Solubilizing
641 and Taste Masking Properties of β -Cyclodextrin: Development of Fast-Dissolving Tablets
642 Containing Extremely Bitter Drug. *Journal of Pharmaceutical Innovation* 9 (4), 309-320
643 **81** Ge, Z. et al. (2015) Preparation and evaluation of orally disintegrating tablets of taste
644 masked phencynonate HCl using ion-exchange resin. *Drug Development and Industrial
645 Pharmacy* 41 (6), 934-941
646 **82** Haraguchi, T. et al. (2014) Evaluation of ebastine-loaded orally disintegrating tablets using
647 new apparatus of detecting disintegration time and e-tongue system. *Journal of Drug
648 Delivery Science and Technology* 24 (6), 684-688
649 **83** Islam, A. et al. (2011) Formulation and evaluation of orodispersible tablet of domperidone.
650 *Dhaka University Journal of Pharmaceutical Sciences* 10 (2), 117-122
651 **84** Yoshida, M. et al. (2015) Evaluation of the palatabilities in 10 different famotidine orally
652 disintegrating tablets by combination of disintegration device and taste sensor. *Drug
653 Development and Industrial Pharmacy* 41 (8), 1387-1392
654 **85** Kim, J.I. et al. (2013) In vitro and in vivo correlation of disintegration and bitter taste masking
655 using orally disintegrating tablet containing ion exchange resin-drug complex. *International
656 Journal of Pharmaceutics* 455 (1-2), 31-39
657 **86** Pimparade, M.B. et al. (2017) Development and evaluation of an oral fast disintegrating anti-
658 allergic film using hot-melt extrusion technology. *Eur J Pharm Biopharm* 119, 81-90
659 **87** Prajapati, V.D. et al. (2018) Pullulan based oral thin film formulation of zolmitriptan:
660 Development and optimization using factorial design. *International Journal of Biological
661 Macromolecules* 107, 2075-2085
662 **88** Shishu et al. (2009) Development of taste-masked fast disintegrating tablets of tinidazole.
663 *Asian Journal of Pharmaceutical Sciences* 4 (1), 39-45
664 **89** Shishu et al. (2009) Taste masking and formulation of ofloxacin rapid disintegrating tablets
665 and oral suspension. *Indian Journal of Pharmaceutical Education and Research* 43 (2), 150-
666 155
667 **90** Abd El-Bary, A. et al. (2019) Effect of casting solvent, film-forming agent and solubilizer on
668 orodispersible films of a polymorphic poorly soluble drug: an in vitro/in silico study. *Drug
669 Development and Industrial Pharmacy* 45 (11), 1751-1769
670 **91** Saab, M.M., M. M. (2019) Disintegration time of orally dissolving films: various
671 methodologies and in-vitro/in-vivo correlation. *Pharmazie* 74 (4), 227-230

672

673 Figure and Table legends

674 *Figure 1: Flow diagram describing the literature review process.*

675

676

677 *Table 1: Frequency of mouthfeel attributes by formulation type evaluated in the studies. (Note that*
678 *some studies reported multiple mouthfeel attributes and 2 studies reported multiple dosage forms).*
679 *ODT – orodispersible tablet, ODF – orodispersible film, MPs – multiparticulate formulation.*

680 *Table 2: In vitro and in vivo methodology used to assess grittiness/roughness. ODT – orodispersible*
681 *tablet, ODF – orodispersible film, SEM – scanning electron microscope, VAS – visual analogue scale,*
682 *API – active pharmaceutical ingredient; MPs – multiparticulate formulation *the direct relevance of*
683 *the measured parameter to grittiness/roughness is unclear.*

684 *Table 3: In vitro and in vivo methodology used to assess adhesiveness/cohesiveness and also*
685 *hardness/softness. ODT – orodispersible tablet, ODF – orodispersible film, SEM – scanning electron*
686 *microscope, API – active pharmaceutical ingredient; *the direct relevance of the measured*
687 *parameter to adhesiveness/cohesiveness or hardness/softness is unclear.*

688 *Table 4: In vitro and in vivo methodology used to assess general palatability/mouthfeel/acceptance.*
689 *ODT – orodispersible tablet, ODF – orodispersible film, MPs – multiparticulate formulation, SEM –*
690 *scanning electron microscope, API – active pharmaceutical ingredient, VAS – visual analogue scale,*
691 *PLS – partial least squares, *the direct relevance of the measured parameter to general*
692 *palatability/mouthfeel/acceptance is unclear.*

693 *Table 5: In vitro and in vivo methodology used to assess ease of swallowing/administration. ODT –*
694 *orodispersible tablet, ODF – orodispersible film, SEM – scanning electron microscope, API – active*
695 *pharmaceutical ingredient, MPs – multiparticulate formulation, VAS – visual analogue scale; *the*
696 *direct relevance of the measured parameter to ease of swallowing/administration is unclear.*

697 *Table 6: In vitro and in vivo methodology used to assess sensation after administration. ODT –*
698 *orodispersible rating tablet, ODF – orodispersible film, MPs – multiparticulate formulation, VAS –*
699 *visual analogue scale; *the direct relevance of the measured parameter to sensation after*
700 *administration is unclear.*

701